Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP-Score.
Adult
Aged
Carcinoma, Hepatocellular
/ mortality
Female
Follow-Up Studies
France
Hepatectomy
Humans
Liver Neoplasms
/ mortality
Liver Transplantation
/ statistics & numerical data
Male
Middle Aged
Neoplasm Recurrence, Local
/ pathology
Retrospective Studies
Waiting Lists
alpha-Fetoproteins
/ analysis
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
22
8
2018
medline:
23
2
2019
entrez:
22
8
2018
Statut:
ppublish
Résumé
In 2012, the Liver Transplant French Study Group built the alpha-fetoprotein-score (AFP-score), which improved significantly the prediction of tumor recurrence in case of liver transplantation for HCC when compared to Milan criteria. The aim of the study was to test the AFP score in case of liver resection (LR) for HCC. From 1990 to 2012, 347 patients underwent a liver resection for HCC developed on chronic liver disease (CLD). All patients with solitary HCC <60 mm were included. The primary end point was to investigate if the AFP-score at the first LR was predictive of recurrence and if recurrence occurred within the AFP-score. The secondary end points were overall survival (OS) and disease-free survival. One hundred and eight patients fulfilled the inclusions criteria. After a median follow-up of 65.4 AFP-score is a useful tool for patients selection after LR for solitary HCC developed on CLD. For patients "in AFP-score," up-front LR provides good survival and allows to avoid up-front LT in case of recurrence.
Sections du résumé
BACKGROUND
In 2012, the Liver Transplant French Study Group built the alpha-fetoprotein-score (AFP-score), which improved significantly the prediction of tumor recurrence in case of liver transplantation for HCC when compared to Milan criteria. The aim of the study was to test the AFP score in case of liver resection (LR) for HCC.
METHODS
From 1990 to 2012, 347 patients underwent a liver resection for HCC developed on chronic liver disease (CLD). All patients with solitary HCC <60 mm were included. The primary end point was to investigate if the AFP-score at the first LR was predictive of recurrence and if recurrence occurred within the AFP-score. The secondary end points were overall survival (OS) and disease-free survival.
RESULTS
One hundred and eight patients fulfilled the inclusions criteria. After a median follow-up of 65.4
CONCLUSION
AFP-score is a useful tool for patients selection after LR for solitary HCC developed on CLD. For patients "in AFP-score," up-front LR provides good survival and allows to avoid up-front LT in case of recurrence.
Identifiants
pubmed: 30128773
doi: 10.1007/s00268-018-4769-5
pii: 10.1007/s00268-018-4769-5
doi:
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-229Références
Lancet. 1999 Nov 6;354(9190):1636-9
pubmed: 10560692
Hepatology. 1999 Dec;30(6):1434-40
pubmed: 10573522
Hepatology. 2000 Apr;31(4):899-906
pubmed: 10733546
Ann Surg. 2003 Jul;238(1):29-34
pubmed: 12832962
Arch Surg. 2003 Jul;138(7):763-9; discussion 769
pubmed: 12860758
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9
pubmed: 14530722
Ann Surg. 2003 Nov;238(5):703-10
pubmed: 14578733
Arch Surg. 2003 Nov;138(11):1198-206; discussion 1206
pubmed: 14609867
Ann Surg. 2003 Dec;238(6):885-92; discussion 892-3
pubmed: 14631225
Lancet. 2003 Dec 6;362(9399):1907-17
pubmed: 14667750
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
pubmed: 15508102
Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103
pubmed: 15508109
Liver Transpl. 2005 Oct;11(10):1242-51
pubmed: 16184539
Ann Surg. 2006 Apr;243(4):499-506
pubmed: 16552201
Ann Surg Oncol. 2007 Sep;14(9):2608-14
pubmed: 17522942
HPB (Oxford). 2002;4(2):99; author reply 99-100
pubmed: 18332933
Liver Transpl. 2008 Jun;14(6):779-88
pubmed: 18508370
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Am J Transplant. 2008 Dec;8(12):2547-57
pubmed: 19032223
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Hepatology. 2009 Nov;50(5):1475-83
pubmed: 19731239
Ann Surg. 2009 Nov;250(5):738-46
pubmed: 19801927
Liver Transpl. 2010 Aug;16(8):925-9
pubmed: 20658555
J Hepatol. 2012 Jan;56(1):14-6
pubmed: 21872558
Ann Surg Oncol. 2012 Mar;19(3):826-33
pubmed: 21879276
Hepatology. 2012 Jan;55(1):132-40
pubmed: 21932387
Surgery. 2012 May;151(5):700-9
pubmed: 22284764
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Am Surg. 2012 Apr;78(4):419-25
pubmed: 22472398
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
Int J Hepatol. 2012;2012:253517
pubmed: 22957260
Ann Surg Oncol. 2013 Apr;20(4):1194-202
pubmed: 22965574
HPB (Oxford). 2013 Feb;15(2):134-41
pubmed: 23036070
Surg Oncol. 2013 Jun;22(2):e23-30
pubmed: 23535302
Liver Cancer. 2012 Sep;1(2):71-82
pubmed: 24159575
Br J Surg. 1986 Jun;73(6):434-8
pubmed: 2424540
Transpl Int. 2014 Jun;27(6):562-9
pubmed: 24606007
J Gastrointest Surg. 2014 Aug;18(8):1469-76
pubmed: 24903846
Hepatology. 2015 Feb;61(2):526-36
pubmed: 25212123
Ann Transl Med. 2015 Jan;3(1):4
pubmed: 25705636
J Hepatol. 2016 Jan;64(1):79-86
pubmed: 26325538
Liver Int. 2016 Nov;36(11):1657-1667
pubmed: 27169841
J Hepatol. 2017 Mar;66(3):552-559
pubmed: 27899297
Liver Transpl. 2017 Jun;23(6):836-844
pubmed: 28295992
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Hepatology. 1994 Jul;20(1 Pt 1):15-20
pubmed: 8020885
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428